Menu

All News

July 21, 2022 • In the News

Marathon Man of Alzheimer’s Research Eyes Finish Line

Dr. Richard Holub from GAP-Net site Neurological Associates of Albany talks about his commitment to finding a cure for Alzheimer’s disease and says he won’t be retiring anytime soon. Dr. Richard Holub has spent the past 40 years dedicated to Alzheimer’s research. He has treated thousands of Alzheimer’s patients and completed more than 125 clinical […]

July 15, 2022 • In the News

GAP Launches Mobile Health Site for Clinical Trials

Individuals who are usually at risk of developing Alzheimer’s can take part in pre-screening visits at every mobile site stop. Global Alzheimer’s Platform Foundation (GAP) has introduced a new mobile health site to lower barriers to the participation of underrepresented communities in Alzheimer’s clinical trials. Around 1% of the African Americans and Hispanics with Alzheimer’s take part […]

July 14, 2022 • Press Releases

GAP Takes Alzheimer’s Clinical Trials On the Road to Remove Barriers to Access

Global Alzheimer’s Platform Foundation’s new mobile research site is taking Alzheimer’s clinical trials on the road to traditionally underrepresented communities. WASHINGTON, DC, July 14, 2022 — Today, Global Alzheimer’s Platform Foundation (GAP) announced the launch of a new mobile health site, which is hitting the road to reduce barriers to clinical trial participation. While more than six […]

June 16, 2022 • In the News

Brigham and Women’s Hospital Hopes to Recruit At-Risk Residents for Global Alzheimer’s Study

GAP-Net Site Brigham and Women’s Hospital Center for Alzheimer Research & Treatment (CART), was featured in their local news station about the importance of volunteer participation in clinical research. A local hospital is now part of a global effort to test a drug that may delay the devastating impact of Alzheimer’s disease. The progressive neurological […]

June 1, 2022 • Press Releases

GNS and the Global Alzheimer’s Platform Foundation® Partner to Advance Alzheimer’s R&D

3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease Somerville, Mass., June 1st, 2022 — GNS, the leader in the use of “Virtual Patients,” Causal AI and simulation technology for biopharmaceutical drug discovery and development, and the Global Alzheimer’s Platform Foundation® (GAP) today […]

May 23, 2022 • In the News

Alzheimer’s Researchers Probe New Treatment Paths

GAP President John Dwyer was quoted in the Wall Street Journal speaking about how the Centers for Medicare and Medicaid Services coverage decision limits Alzheimer’s patients. The commercial failure of Biogen Inc.’s drug Aduhelm is putting new focus on the state of research into the causes of Alzheimer’s disease. More than six million people in the U.S. are […]

May 5, 2022 • In the News

Local Alzheimer’s Center Stands at Forefront of New Treatment Trial

GAP-Net Site, Neurological Associates of Albany, was featured in the news about a new trial they are participating in. Over the last five years, Jim Manuel says he slowly started to lose bits and pieces of his life. Pieces so small, it was easy for his wife and kids to think he was imagining it. […]

April 26, 2022 • In the News

New Alzheimer’s Research Center Targets Patients in the Rio Grande Valley

GAP-Net Site El Faro Health and Therapeutics’ Dr. James Falcon was interviewed about the new research center. Starr County, a rural area along the Texas-Mexico border, has one of the highest rates of Alzheimer’s disease in the country. It’s not clear why. But physicians at a new research and treatment center in the area hope to […]

April 25, 2022 • In the News

Drilling Down into the CMS Aduhelm Decision—A Primer

GAP President John Dwyer was quoted in AlzForum about the Centers for Medicare and Medicaid Services (CMS) National Coverage Decision (NCD) to only cover the drug Aduhlem for those in enrolled in a qualifying clinical trial. The verdict is in—but what now? The Centers for Medicare and Medicaid Services will only cover aducanumab in the context of […]

April 19, 2022 • In the News

Clinical Trial Hoping to Speed Up Alzheimer’s Diagnoses for Minorities

GAP President John Dwyer spoke about the Bio-Hermes study and why enrolling minority populations are a priority. Metro Orlando clinical trial hopes to speed up Alzheimer’s diagnoses for minorities Black people are twice as likely as white people to develop Alzheimer’s disease — Latinx people, 1.5 times as likely. But barriers including access to health […]